Literature DB >> 9338511

The natriuretic response to a dopamine DA1 agonist requires endogenous activation of dopamine DA2 receptors.

A C Eklöf1.   

Abstract

Dopamine produced in the kidney acts as a natriuretic hormone by inhibiting tubular Na+,K+-ATPase activity. Previous in vitro studies have shown that Na+,K+-ATPase activity in the proximal tubule is inhibited by a synergistic action of dopamine 1 (DA1) and dopamine 2 (DA2) receptors. This in vivo study, performed on rats, investigates whether the natriuretic response to DA requires a synergistic action of DA1 and DA2 receptors. The DA1 agonist, fenoldopam, significantly increased urinary sodium excretion, but there was no increase in sodium excretion when a DA1 agonist was given together with a DA2 antagonist. Neither DA1 nor DA2 antagonists had any influence on sodium excretion. The natriuretic response to fenoldopam was also significantly attenuated after the administration of benserazide, which inhibits aromatic acid decarboxylase and thereby suppresses the endogenous production of dopamine. In conclusion, the natriuretic effect of dopamine depends on the activation of both DA1 and DA2 receptors. The DA2 receptor appears to be constitutively activated by endogenous dopamine.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9338511     DOI: 10.1046/j.1365-201X.1997.00166.x

Source DB:  PubMed          Journal:  Acta Physiol Scand        ISSN: 0001-6772


  10 in total

Review 1.  Potential dopamine-1 receptor stimulation in hypertension management.

Authors:  Mohammad Asghar; Seyed K Tayebati; Mustafa F Lokhandwala; Tahir Hussain
Journal:  Curr Hypertens Rep       Date:  2011-08       Impact factor: 5.369

Review 2.  Dopamine receptor-coupling defect in hypertension.

Authors:  Pedro A Jose; Gilbert M Eisner; Robin A Felder
Journal:  Curr Hypertens Rep       Date:  2002-06       Impact factor: 5.369

Review 3.  Oxidative stress in hypertension: role of the kidney.

Authors:  Magali Araujo; Christopher S Wilcox
Journal:  Antioxid Redox Signal       Date:  2013-04-30       Impact factor: 8.401

4.  D1-like dopamine receptors downregulate Na+-K+-ATPase activity and increase cAMP production in the posterior gills of the blue crab Callinectes sapidus.

Authors:  Francis B Arnaldo; Van Anthony M Villar; Prasad R Konkalmatt; Shaun A Owens; Laureano D Asico; John E Jones; Jian Yang; Donald L Lovett; Ines Armando; Pedro A Jose; Gisela P Concepcion
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2014-07-30       Impact factor: 3.619

Review 5.  Dopamine, kidney, and hypertension: studies in dopamine receptor knockout mice.

Authors:  Xiaoyan Wang; Van Anthony M Villar; Ines Armando; Gilbert M Eisner; Robin A Felder; Pedro A Jose
Journal:  Pediatr Nephrol       Date:  2008-07-10       Impact factor: 3.714

6.  An increase in renal dopamine does not stimulate natriuresis after fava bean ingestion.

Authors:  Emily M Garland; Tericka S Cesar; Suzanna Lonce; Marcus C Ferguson; David Robertson
Journal:  Am J Clin Nutr       Date:  2013-04-03       Impact factor: 7.045

Review 7.  Reactive oxygen species and dopamine receptor function in essential hypertension.

Authors:  Chunyu Zeng; Van Anthony M Villar; Peiying Yu; Lin Zhou; Pedro A Jose
Journal:  Clin Exp Hypertens       Date:  2009-04       Impact factor: 1.749

Review 8.  Dysregulation of dopamine-dependent mechanisms as a determinant of hypertension: studies in dopamine receptor knockout mice.

Authors:  Chunyu Zeng; Ines Armando; Yingjin Luo; Gilbert M Eisner; Robin A Felder; Pedro A Jose
Journal:  Am J Physiol Heart Circ Physiol       Date:  2007-12-14       Impact factor: 4.733

Review 9.  Renal Dopamine Receptors and Oxidative Stress: Role in Hypertension.

Authors:  Jian Yang; Van Anthony M Villar; Pedro A Jose; Chunyu Zeng
Journal:  Antioxid Redox Signal       Date:  2020-05-29       Impact factor: 8.401

Review 10.  Renal dopamine receptors, oxidative stress, and hypertension.

Authors:  Santiago Cuevas; Van Anthony Villar; Pedro A Jose; Ines Armando
Journal:  Int J Mol Sci       Date:  2013-08-27       Impact factor: 5.923

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.